phrykt

Royalty Pharma plc (RPRX): who owns it and who trades it

As of Nov 16, 2026, RPRX insiders reported 74 open-market sales worth $92.8M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Terrance P. Coyne (CFO), with $39M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Royalty Pharma

From the latest filings

Overall: more buying than selling. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RPRX

640 funds and institutions reported RPRX shares worth $20.7B at the end of Q2 2026. The largest holder is Morgan Stanley with $2.4B.

10 largest owners, by value

Morgan Stanley$2.4B
Capital International Investors$2B
BlackRock, Inc.$1.6B
FMR LLC (Fidelity)$1.4B
State Street Corp$692M
T. Rowe Price Associates$628M
Swedbank AB$601M
Baillie Gifford & Co$562M
Capital World Investors$534M
Geode Capital Management, LLC$451M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Morgan Stanley42.93M–$2.4B-1%
Capital International Investors35.27M–$2B+1%
BlackRock, Inc.27.83M–$1.6B+7%
FMR LLC (Fidelity)24.51M–$1.4B-3%
State Street Corp12.34M–$692M+12%
T. Rowe Price Associates11.19M–$628M+479%
Swedbank AB10.73M–$601M-7%
Baillie Gifford & Co10.02M–$562M-38%
Capital World Investors9.52M–$534M+18%
Geode Capital Management, LLC8.06M–$451M+2%
Caledonia (Private) Investments Pty Ltd5.78M–$324M-19%
Norges Bank5.34M–$299M–
Vanguard Capital Management LLC4.83M–$271M+7%
Northern Trust Corp4.72M–$265M+24%
Royal London Asset Management Ltd4.32M–$242M+13%
AQR Capital Management LLC4.31M–$241M+14%
Invesco Ltd.4.23M–$237M+13%
Bank of America Corp4.15M–$233M+19%
Legal & General Group Plc3.80M–$213M+13%
Amundi3.72M–$209M+21%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RPRX insiders reported $0 of open-market purchases and $92.8M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$92.8M
74 trades, 5 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Oct 5, 2026
Filed Oct 5, 2026

Purchases and sales by month

$19.7M$19.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 5, 2026Marshall UristVice presidentSale plan4,126$57.10$236KForm 4
Sep 28, 2026Marshall UristVice presidentSale plan4,126$57.88$239KForm 4
Sep 22, 2026Christopher HiteVice presidentSale plan96,073$58.51$5.6MForm 4
Sep 22, 2026Christopher HiteVice presidentSale plan3,927$58.93$231KForm 4
Aug 18, 2026Christopher HiteVice presidentSale plan100,000$59.97$6MForm 4
Aug 13, 2026Terrance P. CoyneCFOSale plan9,230$58.59$541KForm 4
Aug 13, 2026Terrance P. CoyneCFOSale plan1,772$59.14$105KForm 4
Jul 1, 2026Marshall UristVice presidentSale plan9,099$55.88$508KForm 4
Jun 30, 2026Christopher HiteVice presidentSale plan2,554$57.10$146KForm 4
Jun 30, 2026Christopher HiteVice presidentSale plan97,446$56.50$5.5MForm 4
Jun 30, 2026Christopher HiteVice presidentSale plan600$57.09$34.3KForm 4
Jun 30, 2026Christopher HiteVice presidentSale plan29,400$56.44$1.7MForm 4
Jun 24, 2026Marshall UristVice presidentSale plan9,098$55.18$502KForm 4
Jun 23, 2026Christopher HiteVice presidentSale plan117,592$54.47$6.4MForm 4
Jun 23, 2026Christopher HiteVice presidentSale plan32,408$54.11$1.8MForm 4
May 26, 2026Terrance P. CoyneCFOSale plan64,399$53.98$3.5MForm 4
May 20, 2026Marshall UristVice presidentSale plan13,684$52.75$722KForm 4
May 14, 2026Marshall UristVice presidentSale plan13,684$53.06$726KForm 4
May 14, 2026Gregory NordenDirectorSale plan3,045$53.00$161KForm 4
Apr 28, 2026Terrance P. CoyneCFOSale plan1,875$49.78$93.3KForm 4
Apr 28, 2026Terrance P. CoyneCFOSale plan32,916$49.78$1.6MForm 4
Apr 1, 2026Terrance P. CoyneCFOSale plan32,916$48.33$1.6MForm 4
Apr 1, 2026Terrance P. CoyneCFOSale plan1,875$48.33$90.6KForm 4
Mar 23, 2026Terrance P. CoyneCFOSale plan32,916$45.53$1.5MForm 4
Mar 23, 2026Terrance P. CoyneCFOSale plan1,875$45.53$85.4KForm 4
Mar 2, 2026Terrance P. CoyneCFOSale plan1,292$46.67$60.3KForm 4
Mar 2, 2026Terrance P. CoyneCFOSale plan10,429$47.01$490KForm 4
Mar 2, 2026Terrance P. CoyneCFOSale plan22,487$46.67$1MForm 4
Mar 2, 2026Terrance P. CoyneCFOSale plan583$47.01$27.4KForm 4
Feb 23, 2026Terrance P. CoyneCFOSale plan32,916$45.32$1.5MForm 4
Feb 23, 2026Terrance P. CoyneCFOSale plan1,875$45.32$85KForm 4
Feb 4, 2026Terrance P. CoyneCFOSale plan1,087$43.29$47.1KForm 4
Feb 4, 2026Terrance P. CoyneCFOSale plan19,076$43.29$826KForm 4
Feb 3, 2026Terrance P. CoyneCFOSale plan6,195$42.84$265KForm 4
Feb 3, 2026Terrance P. CoyneCFOSale plan108,759$42.84$4.7MForm 4
Feb 2, 2026Terrance P. CoyneCFOSale plan5,843$42.08$246KForm 4
Feb 2, 2026Terrance P. CoyneCFOSale plan102,581$42.08$4.3MForm 4
Jan 30, 2026Marshall UristVice presidentSale plan20,000$41.09$822KForm 4
Jan 23, 2026Marshall UristVice presidentSale plan20,000$40.26$805KForm 4
Jan 20, 2026Terrance P. CoyneCFOSale plan65,832$39.35$2.6MForm 4
Jan 20, 2026Terrance P. CoyneCFOSale plan3,750$39.35$148KForm 4
Jan 16, 2026Marshall UristVice presidentSale plan20,000$39.52$790KForm 4
Jan 9, 2026Marshall UristVice presidentSale plan20,000$40.78$816KForm 4
Jan 2, 2026Terrance P. CoyneCFOSale plan3,750$38.42$144KForm 4
Jan 2, 2026Terrance P. CoyneCFOSale plan65,832$38.42$2.5MForm 4
Jan 2, 2026Marshall UristVice presidentSale plan20,000$38.48$770KForm 4
Dec 26, 2025Marshall UristVice presidentSale plan20,000$39.32$786KForm 4
Dec 19, 2025Marshall UristVice presidentSale plan20,000$38.38$768KForm 4
Dec 18, 2025George W. LloydVice presidentSale plan30,654$38.50$1.2MForm 4
Dec 17, 2025George W. LloydVice presidentSale plan79,346$38.57$3.1MForm 4
Dec 16, 2025Marshall UristVice presidentSale plan20,000$38.32$766KForm 4
Dec 15, 2025Terrance P. CoyneCFOSale plan3,750$38.36$144KForm 4
Dec 15, 2025Terrance P. CoyneCFOSale plan65,832$38.36$2.5MForm 4
Dec 5, 2025Marshall UristVice presidentSale plan23,334$39.15$914KForm 4
Dec 5, 2025Marshall UristVice presidentSale plan18,242$39.15$714KForm 4
Dec 3, 2025George W. LloydVice presidentSale plan110,000$39.77$4.4MForm 4
Dec 1, 2025Terrance P. CoyneCFOSale plan3,750$39.87$150KForm 4
Dec 1, 2025Terrance P. CoyneCFOSale plan65,832$39.87$2.6MForm 4
Dec 1, 2025Marshall UristVice presidentSale plan18,242$39.90$728KForm 4
Dec 1, 2025Marshall UristVice presidentSale plan23,333$39.93$932KForm 4
Nov 24, 2025Terrance P. CoyneCFOSale plan55,146$38.67$2.1MForm 4
Nov 24, 2025Terrance P. CoyneCFOSale plan624$37.96$23.7KForm 4
Nov 24, 2025Terrance P. CoyneCFOSale plan3,126$38.67$121KForm 4
Nov 24, 2025Terrance P. CoyneCFOSale plan10,686$37.96$406KForm 4
Nov 19, 2025George W. LloydVice presidentSale plan4,599$39.01$179KForm 4
Nov 19, 2025George W. LloydVice presidentSale plan230$39.03$9KForm 4
Nov 19, 2025George W. LloydVice presidentSale plan47,798$38.28$1.8MForm 4
Nov 19, 2025George W. LloydVice presidentSale plan4,628$39.01$181KForm 4
Nov 19, 2025George W. LloydVice presidentSale plan47,401$38.28$1.8MForm 4
Nov 19, 2025George W. LloydVice presidentSale plan25,530$38.28$977KForm 4
Nov 19, 2025George W. LloydVice presidentSale plan2,470$39.01$96.4KForm 4
Nov 19, 2025George W. LloydVice presidentSale plan2,770$38.29$106KForm 4
Nov 17, 2025Terrance P. CoyneCFOSale plan65,844$39.30$2.6MForm 4
Nov 17, 2025Terrance P. CoyneCFOSale plan3,750$39.30$147KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Terrance P. CoyneEVP & CFO–$39MAug 13, 2026
Christopher HiteEVP & Chairman, Partnering–$27.4MSep 22, 2026
George W. LloydEVP, Investments & CLO–$13.8MDec 18, 2025
Marshall UristEVP, Research & Investments–$12.5MOct 5, 2026
Gregory NordenDirector–$161KMay 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RPRX short interest

13.08M RPRX shares are sold short. Over the last 12 reports the number of shares short went up 3%.

As of Oct 30, 2026, 13.08M RPRX shares were sold short, up 1.8% from the report before. At the average daily volume of 3.30M shares, buying them all back would take about 4.0 trading days (days to cover).

Shares short

13.08MMay 15Oct 3013.44M

Days to cover

4.0May 15Oct 305.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202613.08M–+2%3.30M4.0
Oct 15, 202612.84M–-0%3.00M4.3
Sep 30, 202612.89M–+11%2.90M4.4
Sep 15, 202611.65M–-2%3.59M3.2
Aug 31, 202611.90M–+3%2.36M5.0
Aug 14, 202611.61M–+9%3.08M3.8
Jul 31, 202610.67M–-12%2.62M4.1
Jul 15, 202612.13M–-2%2.73M4.4
Jun 30, 202612.44M–+12%4.18M3.0
Jun 15, 202611.13M–-4%3.67M3.0
May 29, 202611.59M–-9%4.69M2.5
May 15, 202612.68M–-8%3.82M3.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Royalty Pharma company events

Royalty Pharma filed 9 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jun 4, 2026VoteReported shareholder vote results. Filing
  4. May 28, 2026AgreementRoyalty Pharma plc, Royalty Pharma Holdings Ltd, a non-wholly owned consolidated subsidiary of the Company, and Royalty Pharma Manager, LLC entered into that certain Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent and the other lenders thereto. Filing
  5. May 6, 2026ResultsReleased financial results. Filing
  6. Apr 13, 2026AnnouncementShared information with investors. Filing
  7. Feb 11, 2026ResultsReleased financial results. Filing
  8. Dec 22, 2025LeadershipGeorge W. Lloyd, age 66, informed Royalty Pharma plc of his decision to transition from his role of Executive Vice President and Chief Legal Officer effective December 31, 2025. Filing
  9. Dec 22, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Royalty Pharma financials

Famous investors that hold RPRX

6 of the 50 well-known investors we track reported holding RPRX in their latest 13F filing. The largest position is Ken Griffin's, worth $85.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.47M$85.9M0.0%+9%
Steve Cohen · Point72 Asset ManagementQ3 20261.12M$65.6M0.1%+954%
Jim Simons · Renaissance TechnologiesQ3 2026591,100$34.5M0.0%-69%
Paul Tudor Jones · Tudor Investment CorpQ3 2026510,736$29.8M0.1%-16%
Ray Dalio · Bridgewater AssociatesQ3 2026474,521$27.7M0.1%+116%
Israel Englander · Millennium ManagementQ3 202665,043$3.8M0.0%+440%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RPRX in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A4.3%
Nov 5, 2026FMR LLC13G/A4.3%

Questions about Royalty Pharma plc (RPRX) stock

Who owns the most RPRX stock?

The largest reported owner of Royalty Pharma plc (RPRX) is Morgan Stanley. In total, 640 funds and institutions reported holding RPRX at the end of Q2 2026. See the largest owners.

Are RPRX insiders buying or selling?

In the last 12 months, RPRX insiders reported no open-market purchases and 74 sales worth $92.8M. The latest trade was on Oct 5, 2026. See every trade.

What is the short interest in RPRX?

As of Oct 30, 2026, 13.08M RPRX shares were sold short, up 1.8% from the report before. At the average daily volume of 3.30M shares, buying them all back would take about 4.0 trading days (days to cover). See the history.

Which famous investors hold RPRX?

6 of the 50 well-known investors we track reported RPRX in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $85.9M. See all holders.

Executive pay

Royalty Pharma's chief executive was paid a total of $938K for the year ended Dec 31, 2025. In the last 12 months, Royalty Pharma's executives and directors bought no stock on the open market and sold $92.8M.

Chief executive, total pay$938KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$82.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.